Answers are grounded in this paper and cite their sources.
Almost 11 years of follow-up showed that the efficacy of imatinib persisted over time and that long-term administration of imatinib was not associated with unacceptable cumulative or late toxic effects. (Funded by Novartis Pharmaceuticals; IRIS ClinicalTrials.gov numbers, NCT00006343 and NCT00333840 .).
No takes yet. Share an insight, caveat, or question.
Hochhaus et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: